Eve St-Hilaire
Overview
Explore the profile of Eve St-Hilaire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wan B, Alibhai S, Chodirker L, Mozessohn L, Geddes M, Zhu N, et al.
Leuk Lymphoma
. 2024 Nov;
66(2):279-288.
PMID: 39520728
Myelodysplastic syndromes (MDSs) treatment focuses on improving quality of life (QOL), affected by anemia and transfusion dependence (TD). Using the MDS-CAN registry, we studied how changes in transfusion status -...
2.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, et al.
J Pharm Pharm Sci
. 2023 Dec;
26:12078.
PMID: 38152647
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first...
3.
Buckstein R, Chodirker L, Yee K, Geddes M, Leitch H, Christou G, et al.
Leuk Lymphoma
. 2023 Jan;
64(3):651-661.
PMID: 36606533
Many patients with lower-risk myelodysplastic syndromes (LR MDS) require long-term red blood cell (RBC) transfusions to manage anemia. The consequences of RBC transfusions in LR MDS with ring sideroblasts (LR...
4.
Buckstein R, Chodirker L, Mozessohn L, Yee K, Geddes M, Zhu N, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3165-3174.
PMID: 36095125
Patients with lower-risk (LR) myelodysplastic syndromes (MDS) with ring sideroblasts (RS) have better prognosis than those without RS, but how they fare over time is not fully understood. This study's...
5.
Teichman J, Geddes M, Zhu N, Keating M, Sabloff M, Christou G, et al.
Haematologica
. 2022 Aug;
108(2):532-542.
PMID: 35979720
Iron overload (IO) reflected by elevated ferritin is associated with increased mortality in myelodysplastic syndromes (MDS), however, ferritin is an imperfect metric. Elevated labile plasma iron correlates with clinical outcomes...
6.
Bourcier L, St-Hilaire E, Leblanc M, Picard L
SAGE Open Med Case Rep
. 2021 Jun;
9:2050313X211025111.
PMID: 34178352
Checkpoint inhibitor immunotherapy has recently started to play a fundamental role in the management of metastatic melanoma. It is however accountable for many undesirable adverse effects involving many organ systems....
7.
Amitai I, Geddes M, Zhu N, Keating M, Sabloff M, Christou G, et al.
Br J Haematol
. 2021 Jun;
194(2):319-324.
PMID: 34060069
The incorporation of patient-reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we...
8.
Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, et al.
Clin Transl Med
. 2021 May;
11(4):e401.
PMID: 33931971
Background: Therapeutic resistance is the main cause of death in metastatic colorectal cancer. To investigate genomic plasticity, most specifically of metastatic lesions, associated with response to first-line systemic therapy, we...
9.
Wan B, Nazha A, Starkman R, Alibhai S, Wells R, Geddes M, et al.
Leukemia
. 2020 Aug;
34(12):3434-3438.
PMID: 32855438
No abstract available.
10.
Houston B, Jayakar J, Wells R, Lenis M, Zhang L, Zhu N, et al.
Ann Hematol
. 2017 Oct;
96(12):2025-2029.
PMID: 28975386
Prediction of response to erythropoietin stimulating agents (ESAs) in anemic MDS patients is often based on the Nordic score. We wished to validate the Nordic score (IWG 2006 response criteria)...